Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Revenue of Chinook Therapeutics, Inc. (KDNY)
Revenue in 2022 (TTM): $6.13 M
According to Chinook Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $6.13 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Chinook Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $6.13 M | $4.41 M | $-164,196,000 | $-180,274,000 | $-184,615,000 |
| 2021 | $51.63 M | $49.94 M | $-57,171,000 | $-99,208,000 | $-101,301,000 |
| 2020 | $827 K | $405 K | $-53,982,000 | $-83,625,000 | $-81,622,000 |
| 2019 | $17.26 M | $16.7 M | $-19,446,000 | $-46,519,000 | $-46,851,000 |
| 2018 | $15.09 M | $14.5 M | $-101,360,000 | $-96,140,000 | $-95,357,000 |
| 2017 | $17.24 M | $16.68 M | $-106,453,000 | $-103,227,000 | $-91,863,000 |
| 2016 | $50.68 M | $50.13 M | $-71,863,000 | $-69,684,000 | $-91,148,000 |
| 2015 | $72.98 M | $72.89 M | $-13,564,000 | $-39,308,000 | $-39,209,000 |